DDD Partners LLC Decreases Stake in Elanco Animal Health Incorporated $ELAN

Key Points

• DDD Partners cut its stake in Elanco by 47.1%, selling 826,351 shares and finishing the quarter with 927,018 shares (about 0.19% of Elanco, ~$20.98M), making ELAN its 19th-largest holding.
• Elanco beat quarterly expectations (EPS $0.13 vs. $0.11) with revenue of $1.14B (+12.2% YoY) and issued guidance of $0.33–$0.36 for Q1 2026 and $1.00–$1.06 for FY2026.
• Institutional activity is notable—Goldman Sachs more than doubled its position to ~4.79M shares while overall institutional ownership is ~97.48%; analysts' consensus is a "Moderate Buy" with an average target of $27.67.

DDD Partners LLC lessened its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 47.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 927,018 shares of the company's stock after selling 826,351 shares during the quarter. Elanco Animal Health accounts for approximately 1.3% of DDD Partners LLC's portfolio, making the stock its 19th biggest position. DDD Partners LLC owned approximately 0.19% of Elanco Animal Health worth $20,978,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Elanco Animal Health in the 1st quarter valued at about $2,065,000. Goldman Sachs Group Inc. lifted its position in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Empowered Funds LLC lifted its position in shares of Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock worth $166,000 after purchasing an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Elanco Animal Health by 4.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock worth $18,830,000 after purchasing an additional 76,408 shares during the last quarter. Finally, M&T Bank Corp lifted its position in shares of Elanco Animal Health by 4.0% during the 2nd quarter. M&T Bank Corp now owns 25,029 shares of the company's stock worth $358,000 after purchasing an additional 971 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Price Performance

Shares of ELAN opened at $23.47 on Friday. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $27.72. The stock has a market cap of $11.67 billion, a PE ratio of -48.89, a price-to-earnings-growth ratio of 3.00 and a beta of 1.88. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08. The firm has a fifty day moving average price of $24.46 and a 200 day moving average price of $22.91.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm had revenue of $1.14 billion during the quarter, compared to analysts' expectations of $1.09 billion. During the same period in the previous year, the company earned $0.14 earnings per share. Elanco Animal Health's quarterly revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ELAN shares. Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 25th. UBS Group reaffirmed a "buy" rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. JPMorgan Chase & Co. boosted their target price on Elanco Animal Health from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Thursday, February 19th. Weiss Ratings restated a "sell (d+)" rating on shares of Elanco Animal Health in a research note on Friday, March 27th. Finally, KeyCorp boosted their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $27.67.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.